series-b
Stage
About
Oblenio Bio develops a tri-specific T-cell engager antibody therapy designed to reset the immune system and treat refractory autoimmune diseases by depleting pathological B-cells and plasma cells to achieve long-term drug-free remission.
Explore Oblenio Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.